Abstract:Quercetin decreases ACE2, TMPRSS2, and ADAM17 in human Calu‐3 lung cells cultured at an air–liquid interface (Calu‐3‐ALI) but has no effect on severe acute respiratory syndrome coronavirus 2 infection. Created with BioRender.com. Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) binds to angiotensin‐converting enzyme 2 (ACE2) on host cells, via its spike protein, and transmembrane protease, serine 2 (TMPRSS2) cleaves the spike‐ACE2 complex to facilitate virus entry. As rate‐limiting steps for virus entry, modulation of ACE2 and/or TMPRSS2 may decrease SARS‐CoV‐2 infectivity and COVID‐19 severity. In silico modeling suggested the natural bioactive flavonoid quercetin can bind to ACE2 and a recent randomized clinical trial demonstrated that oral supplementation with quercetin increased COVID‐19 recovery. A range of cultured human cells were assessed for co‐expression of ACE2 and TMPRSS2. Immortalized Calu‐3 lung cells, cultured and matured at an air–liquid interface (Calu‐3‐ALIs), were established as the most appropriate. Primary bronchial epithelial cells (PBECs) were obtained from healthy adult males (N = 6) and cultured under submerged conditions to corroborate the outcomes. Upon maturation or reaching 80% confluence, respectively, the Calu‐3‐ALIs and PBECs were treated with quercetin, and mRNA and protein expression were assessed by droplet digital PCR and ELISA, respectively. SARS‐CoV‐2 infectivity, and the effects of pre‐ and co‐treatment with quercetin, was assessed by median tissue culture infectious dose assay. Quercetin dose‐dependently decreased ACE2 and TMPRSS2 mRNA and protein in both Calu‐3‐ALIs and PBECs after 4 h, while TMPRSS2 remained suppressed in response to prolonged treatment with lower doses (twice daily for 3 days). Quercetin also acutely decreased ADAM17 mRNA, but not ACE, in Calu‐3‐ALIs, and this warrants further investigation. Calu‐3‐ALIs, but not PBECs, were successfully infected with SARS‐CoV‐2; however, quercetin had no antiviral effect, neither directly nor indirectly through downregulation of ACE2 and TMPRSS2. Calu‐3‐ALIs were reaffirmed to be an optimal cell model for research into the regulation of ACE2 and TMPRSS2, without the need for prior genetic modification, and will prove valuable in future coronavirus and respiratory infectious disease work. However, our data demonstrate that a significant decrease in the expression of ACE2 and TMPRSS2 by a promising prophylactic candidate may not translate to infection prevention.

Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

Quinine Inhibits Infection of Human Cell Lines with SARS-CoV-2

New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?

Potential Antiviral Effect of Chloroquine Therapy against SARS-CoV-2 Infection

In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine

Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Antimalarials are not Effective as Pre-Exposure Prophylaxis for COVID-19: A Retrospective Matched Control Study

Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19

The Effects of Chloroquine and Hydroxychloroquine on ACE2-Related Coronavirus Pathology and the Cardiovascular System: An Evidence-Based Review

Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine

Distinct Mechanisms for TMPRSS2 Expression Explain Organ-Specific Inhibition of SARS-CoV-2 Infection by Enzalutamide

Chloroquine Up-regulates Expression of SARS-CoV-2 receptor Angiotensin Converting Enzyme-2 in Endothelial Cells

Suramin Inhibits SARS-CoV-2 Infection in Cell Culture by Interfering with Early Steps of the Replication Cycle

Antimalarial Artefenomel Inhibits Human SARS-CoV-2 Replication in Cells while Suppressing the Receptor ACE2

The flavonoid quercetin decreases ACE2 and TMPRSS2 expression but not SARS‐CoV‐2 infection in cultured human lung cells

Inhibitors of endosomal acidification suppress SARS-CoV-2 replication and relieve viral pneumonia in hACE2 transgenic mice

Prophylactic Effect of Chloroquine and Hydroxychloroquine on COVID-19 Treatment

Chloroquine and Hydroxychloroquine As ACE2 Blockers to Inhibit Viropexis of 2019-Ncov Spike Pseudotyped Virus

Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19